Drug intelligence / Profile preview

erythromycin ethylsuccinate

Development stage
Approved
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral
01

Overview

Erythromycin ethylsuccinate is a macrolide antibiotic and a prodrug ester of erythromycin. It exerts its antibacterial effect by binding to the 50S ribosomal subunit of susceptible bacteria, specifically targeting the 23S ribosomal RNA, which inhibits RNA-dependent protein synthesis and prevents bacterial growth. It is indicated for a variety of infections, including respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases caused by organisms such as *Streptococcus pyogenes*, *Streptococcus pneumoniae*, *Mycoplasma pneumoniae*, and *Chlamydia trachomatis*. It is frequently utilized as an alternative treatment for patients with penicillin hypersensitivity. The ethylsuccinate ester is formulated to improve oral absorption and reduce the bitter taste associated with erythromycin base.

Brand names
E.E.S.EryPedErythrocin Ethylsuccinate
Other names
erythromycin ethylsuccinateerythromycin 2'-(ethyl succinate)erythromycin ethyl succinate
02

Targets

23S rRNA (23S ribosomal RNA)

Beyond the preview

Go deeper on erythromycin ethylsuccinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythromycin ethylsuccinate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call